Unknown

Dataset Information

0

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.


ABSTRACT: Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC.

SUBMITTER: Venur VA 

PROVIDER: S-EPMC5395273 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.

Venur Vyshak Alva VA   Joshi Monika M   Nepple Kenneth G KG   Zakharia Yousef Y  

Drug design, development and therapy 20170411


Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3  ...[more]

Similar Datasets

| S-EPMC5614734 | biostudies-literature
| S-EPMC4939993 | biostudies-literature
| S-EPMC5503498 | biostudies-literature
| S-EPMC5933337 | biostudies-literature
| S-EPMC5167476 | biostudies-literature
| S-EPMC9208469 | biostudies-literature
| S-EPMC5221559 | biostudies-literature
| S-EPMC6306059 | biostudies-literature
| S-EPMC5749544 | biostudies-literature
| S-EPMC5587117 | biostudies-literature